e*n
发帖数: 1511 | 1 Not sure why my post yesterday didn't come through; brief summary this
time. Helicos gave a phenomenal presentation at the American
Association for Cancer Research annual meeting yesterday. Any of the
~1,000 audience members who witnessed the session should chime in to
validate this post. To me, they presented themselves as the clearly
superior sequencing technology in front of a very important audience
that includes the medical and academic institutions investing heavily
in sequencing technology.
To convey just a few of the WOW moments in Dr. Milos's presentation:
1) Accuracy is > 99.995%, which is reported to be unmatched by other
sequencing companies. 2) The HeliScope can read DNA or RNA from
formalin fixed paraffin-embedded (FFPE) samples...which opens up a
potentially huge market in the cancer arena. 3) HeliScope can be used
to determine copy number variation, RNA expression, methylation
status, regulatory binding sites (ChIP seq), and many other medically-
and scientifically-relevant parameters. Noteably, HLCS reports that
about 50% of the transcriptome is non-coding RNA! This is causing a
commotion in the field and is bound to be a huge boon to the study of
non-coding RNA. 4) The HeliScope requires fewer cells than other
platforms, enabling the study of prescious/limited specimens such as
stem cells. 5) Easiest workflow. 6) The only platform that performs
DIRECT RNA sequencing (and, therefore, presumably yields the highest
quality data). ” |
|
